{"id":"https://openalex.org/W2136103407","doi":"https://doi.org/10.1158/1078-0432.ccr-08-1930","title":"Clinical and Biological Effects of Valproic Acid as a Histone Deacetylase Inhibitor on Tumor and Surrogate Tissues: Phase I/II Trial of Valproic acid and Epirubicin/FEC","display_name":"Clinical and Biological Effects of Valproic Acid as a Histone Deacetylase Inhibitor on Tumor and Surrogate Tissues: Phase I/II Trial of Valproic acid and Epirubicin/FEC","publication_year":2009,"publication_date":"2009-03-25","ids":{"openalex":"https://openalex.org/W2136103407","doi":"https://doi.org/10.1158/1078-0432.ccr-08-1930","mag":"2136103407","pmid":"https://pubmed.ncbi.nlm.nih.gov/19318486"},"language":"en","primary_location":{"id":"doi:10.1158/1078-0432.ccr-08-1930","doi":"https://doi.org/10.1158/1078-0432.ccr-08-1930","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1078-0432.ccr-08-1930","pdf_url":null,"source":{"id":"https://openalex.org/S183149254","display_name":"Clinical Cancer Research","issn_l":"1078-0432","issn":["1078-0432","1557-3265"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Cancer Research","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5083373965","display_name":"Pamela N. M\u00fcnster","orcid":"https://orcid.org/0000-0002-2074-0984","observed_orcids":["https://orcid.org/0000-0002-2074-0984","https://orcid.org/0009-0009-4141-2312"]},"institutions":[{"id":"https://openalex.org/I180670191","display_name":"University of California, San Francisco","ror":"https://ror.org/043mz5j54","country_code":"US","type":"education","lineage":["https://openalex.org/I180670191"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Pamela Munster","raw_affiliation_strings":["1Division of Hematology Oncology, University of California, San Francisco, Divisadero, San Francisco, California; and","Division of Hematology Oncology, University of California, San Francisco, Divisadero, San Francisco, California 94143-1711, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Division of Hematology Oncology, University of California, San Francisco, Divisadero, San Francisco, California; and","institution_ids":["https://openalex.org/I180670191"]},{"raw_affiliation_string":"Division of Hematology Oncology, University of California, San Francisco, Divisadero, San Francisco, California 94143-1711, USA","institution_ids":["https://openalex.org/I180670191"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5064856723","display_name":"Douglas C. Marchion","orcid":"https://orcid.org/0009-0003-7673-0149","observed_orcids":["https://orcid.org/0009-0003-7673-0149"]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Douglas Marchion","raw_affiliation_strings":["2Experimental Therapeutics, Department of Interdisciplinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Experimental Therapeutics, Department of Interdisciplinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida","institution_ids":["https://openalex.org/I3019308854"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5064405251","display_name":"Elona Bi\u00e7aku","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Elona Bicaku","raw_affiliation_strings":["2Experimental Therapeutics, Department of Interdisciplinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Experimental Therapeutics, Department of Interdisciplinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida","institution_ids":["https://openalex.org/I3019308854"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045669379","display_name":"Mira Lacevic","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mira Lacevic","raw_affiliation_strings":["2Experimental Therapeutics, Department of Interdisciplinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Experimental Therapeutics, Department of Interdisciplinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida","institution_ids":["https://openalex.org/I3019308854"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009314752","display_name":"Jongphil Kim","orcid":"https://orcid.org/0000-0002-7430-2226","observed_orcids":["https://orcid.org/0000-0002-7430-2226"]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jongphil Kim","raw_affiliation_strings":["2Experimental Therapeutics, Department of Interdisciplinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Experimental Therapeutics, Department of Interdisciplinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida","institution_ids":["https://openalex.org/I3019308854"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5007883302","display_name":"Barbara Ann Centeno","orcid":"https://orcid.org/0009-0007-7668-2748","observed_orcids":["https://orcid.org/0009-0007-7668-2748"]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Barbara Centeno","raw_affiliation_strings":["2Experimental Therapeutics, Department of Interdisciplinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Experimental Therapeutics, Department of Interdisciplinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida","institution_ids":["https://openalex.org/I3019308854"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5018322482","display_name":"ADIL I. DAUD","orcid":"https://orcid.org/0000-0002-6617-8421","observed_orcids":["https://orcid.org/0000-0002-6617-8421"]},"institutions":[{"id":"https://openalex.org/I180670191","display_name":"University of California, San Francisco","ror":"https://ror.org/043mz5j54","country_code":"US","type":"education","lineage":["https://openalex.org/I180670191"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Adil Daud","raw_affiliation_strings":["1Division of Hematology Oncology, University of California, San Francisco, Divisadero, San Francisco, California; and"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Division of Hematology Oncology, University of California, San Francisco, Divisadero, San Francisco, California; and","institution_ids":["https://openalex.org/I180670191"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5030296219","display_name":"Anthony M. Neuger","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Anthony Neuger","raw_affiliation_strings":["2Experimental Therapeutics, Department of Interdisciplinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Experimental Therapeutics, Department of Interdisciplinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida","institution_ids":["https://openalex.org/I3019308854"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111541235","display_name":"Susan E. Minton","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Susan Minton","raw_affiliation_strings":["2Experimental Therapeutics, Department of Interdisciplinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Experimental Therapeutics, Department of Interdisciplinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida","institution_ids":["https://openalex.org/I3019308854"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5102841436","display_name":"Daniel M. Sullivan","orcid":"https://orcid.org/0009-0003-0951-9781","observed_orcids":["https://orcid.org/0009-0003-0951-9781","https://orcid.org/0000-0002-2183-1773"]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Daniel Sullivan","raw_affiliation_strings":["2Experimental Therapeutics, Department of Interdisciplinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Experimental Therapeutics, Department of Interdisciplinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida","institution_ids":["https://openalex.org/I3019308854"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":7.2394,"has_fulltext":false,"cited_by_count":150,"citation_normalized_percentile":{"value":0.98212321,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":93,"max":99},"biblio":{"volume":"15","issue":"7","first_page":"2488","last_page":"2496"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11736","display_name":"Histone Deacetylase Inhibitors Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11736","display_name":"Histone Deacetylase Inhibitors Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10269","display_name":"Epigenetics and DNA Methylation","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10183","display_name":"Breast Cancer Treatment Studies","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/valproic-acid","display_name":"valproic acid","score":1.0},{"id":"https://openalex.org/keywords/histone-deacetylase-inhibitors","display_name":"histone deacetylase inhibitors","score":0.9810000061988831},{"id":"https://openalex.org/keywords/hdac2","display_name":"HDAC2","score":0.8199999928474426},{"id":"https://openalex.org/keywords/hdac6","display_name":"HDAC6","score":0.9990000128746033},{"id":"https://openalex.org/keywords/histone-acetylation","display_name":"histone acetylation","score":0.8870000243186951},{"id":"https://openalex.org/keywords/epirubicin","display_name":"epirubicin","score":0.8939999938011169},{"id":"https://openalex.org/keywords/fec-chemotherapy","display_name":"FEC chemotherapy","score":0.8190000057220459},{"id":"https://openalex.org/keywords/breast-cancer","display_name":"breast cancer","score":0.9629999995231628},{"id":"https://openalex.org/keywords/solid-tumors","display_name":"solid tumors","score":0.7950000166893005},{"id":"https://openalex.org/keywords/peripheral-blood-mononuclear-cells","display_name":"peripheral blood mononuclear cells","score":0.8289999961853027},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.7540000081062317},{"id":"https://openalex.org/keywords/pharmacodynamics","display_name":"pharmacodynamics","score":0.9179999828338623},{"id":"https://openalex.org/keywords/neutropenia","display_name":"neutropenia","score":0.7099999785423279},{"id":"https://openalex.org/keywords/sleepiness","display_name":"sleepiness","score":0.8090000152587891},{"id":"https://openalex.org/keywords/drug-drug-interactions","display_name":"drug-drug interactions","score":0.48899999260902405},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.5540000200271606}],"concepts":[{"id":"https://openalex.org/C2777172819","wikidata":"https://www.wikidata.org/wiki/Q240642","display_name":"Valproic Acid","level":3,"score":0.8968127965927124},{"id":"https://openalex.org/C2776202225","wikidata":"https://www.wikidata.org/wiki/Q3569101","display_name":"Histone deacetylase inhibitor","level":5,"score":0.638076901435852},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.6197547316551208},{"id":"https://openalex.org/C2778305200","wikidata":"https://www.wikidata.org/wiki/Q174378","display_name":"Histone deacetylase","level":4,"score":0.5900442004203796},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5559449791908264},{"id":"https://openalex.org/C2780835546","wikidata":"https://www.wikidata.org/wiki/Q425122","display_name":"Epirubicin","level":4,"score":0.5395320057868958},{"id":"https://openalex.org/C2776262904","wikidata":"https://www.wikidata.org/wiki/Q905901","display_name":"Vorinostat","level":5,"score":0.49039316177368164},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.37717297673225403},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.281794011592865},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.269181489944458},{"id":"https://openalex.org/C64927066","wikidata":"https://www.wikidata.org/wiki/Q36293","display_name":"Histone","level":3,"score":0.18423154950141907},{"id":"https://openalex.org/C2778186239","wikidata":"https://www.wikidata.org/wiki/Q41571","display_name":"Epilepsy","level":2,"score":0.10077917575836182},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.09520590305328369},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.06336873769760132},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.0},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D001792","descriptor_name":"Blood Platelets","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D003520","descriptor_name":"Cyclophosphamide","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D004791","descriptor_name":"Enzyme Inhibitors","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D004791","descriptor_name":"Enzyme Inhibitors","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D004791","descriptor_name":"Enzyme Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005472","descriptor_name":"Fluorouracil","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D006657","descriptor_name":"Histones","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007962","descriptor_name":"Leukocytes","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D014635","descriptor_name":"Valproic Acid","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D014635","descriptor_name":"Valproic Acid","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D014635","descriptor_name":"Valproic Acid","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D015251","descriptor_name":"Epirubicin","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D015251","descriptor_name":"Epirubicin","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D015251","descriptor_name":"Epirubicin","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D056572","descriptor_name":"Histone Deacetylase Inhibitors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1158/1078-0432.ccr-08-1930","doi":"https://doi.org/10.1158/1078-0432.ccr-08-1930","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1078-0432.ccr-08-1930","pdf_url":null,"source":{"id":"https://openalex.org/S183149254","display_name":"Clinical Cancer Research","issn_l":"1078-0432","issn":["1078-0432","1557-3265"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Cancer Research","raw_type":"journal-article"},{"id":"pmid:19318486","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/19318486","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical cancer research : an official journal of the American Association for Cancer Research","raw_type":"Clinical Trial, Phase I"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[{"id":"https://openalex.org/G1806395157","display_name":"Potentiation of Topo Inhibitors by the HDACi, SAHA","funder_award_id":"R21CA112913","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"},{"id":"https://openalex.org/G8179067745","display_name":"Potentiation of Topo Inhibitors by HDAC Inhibitors","funder_award_id":"R21CA105875","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"}],"funders":[{"id":"https://openalex.org/F4320337351","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":50,"referenced_works":["https://openalex.org/W36881043","https://openalex.org/W1508389343","https://openalex.org/W1641419369","https://openalex.org/W1935102817","https://openalex.org/W1946962189","https://openalex.org/W1960984881","https://openalex.org/W1968489542","https://openalex.org/W1971775618","https://openalex.org/W1973899902","https://openalex.org/W1976298557","https://openalex.org/W1984116181","https://openalex.org/W1993510744","https://openalex.org/W2003907016","https://openalex.org/W2004800182","https://openalex.org/W2015886726","https://openalex.org/W2020278966","https://openalex.org/W2022285476","https://openalex.org/W2029816768","https://openalex.org/W2033747485","https://openalex.org/W2034076446","https://openalex.org/W2035104898","https://openalex.org/W2038439057","https://openalex.org/W2050931169","https://openalex.org/W2052181006","https://openalex.org/W2063819389","https://openalex.org/W2064310618","https://openalex.org/W2070433411","https://openalex.org/W2071115015","https://openalex.org/W2071888464","https://openalex.org/W2100618837","https://openalex.org/W2101704140","https://openalex.org/W2104337841","https://openalex.org/W2106357158","https://openalex.org/W2106775330","https://openalex.org/W2107040737","https://openalex.org/W2111715042","https://openalex.org/W2118195221","https://openalex.org/W2135619784","https://openalex.org/W2139248078","https://openalex.org/W2148104091","https://openalex.org/W2148471976","https://openalex.org/W2157511493","https://openalex.org/W2160173183","https://openalex.org/W2164382188","https://openalex.org/W2165455805","https://openalex.org/W2169409181","https://openalex.org/W2169724454","https://openalex.org/W2170925020","https://openalex.org/W2171185186","https://openalex.org/W4230677464"],"related_works":["https://openalex.org/W2171185186","https://openalex.org/W2343421709","https://openalex.org/W2246142081","https://openalex.org/W2277443631","https://openalex.org/W2071888464","https://openalex.org/W2099235218","https://openalex.org/W2111715042","https://openalex.org/W2528161472","https://openalex.org/W2164311213","https://openalex.org/W2227728127"],"abstract_inverted_index":{"PURPOSE:":[0],"The":[1],"aim":[2],"was":[3,46,221],"to":[4,39,224,229],"study":[5],"the":[6,12,76,114,154,170],"biological":[7],"and":[8,59,63,69,73,90,95,98,103,187,202,212,220,241],"molecular":[9],"effects":[10,77],"of":[11,32,52,78,101,123,149,164,177,200],"histone":[13,82,250],"deacetylase":[14],"(HDAC)":[15],"inhibitor,":[16,240],"valproic":[17,33,53,67,79,138,184,217],"acid,":[18],"in":[19,84,113,147,162,209,213,252],"patients":[20,110,127,152,168],"with":[21,56,118,173,196,216],"solid":[22,253],"tumor":[23,91,210,249,254],"malignancies.":[24,255],"EXPERIMENTAL":[25],"DESIGN:":[26],"A":[27],"phase":[28,115,155],"I":[29,116,156],"dose":[30,50,171],"escalation":[31],"acid":[34,54,68,80,139,191,218,234],"given":[35],"on":[36,81],"days":[37],"1":[38],"3":[40],"followed":[41,47,140],"by":[42,48,141],"epirubicin":[43,70],"(day":[44],"3)":[45],"a":[49,119,174,236,246,262],"expansion":[51,122,172],"combined":[55],"5-fluorouracil,":[57],"epirubicin,":[58],"cyclophosphamide":[60],"(FEC100).":[61],"Pharmacodynamic":[62],"pharmacokinetic":[64],"studies":[65],"entailed":[66],"plasma":[71,192],"levels":[72,193,219],"their":[74],"interaction,":[75],"acetylation":[83,208,251],"peripheral":[85],"blood":[86],"mononuclear":[87],"cells":[88,92],"(PBMC)":[89],"at":[93,169],"baseline":[94,99,225],"day":[96],"3,":[97],"expression":[100],"HDAC2":[102,226,256],"HDAC6":[104,230],"as":[105,245,261],"therapeutic":[106,264],"targets.":[107],"RESULTS:":[108],"Forty-four":[109],"were":[111,145,160,183,194],"enrolled":[112],"part,":[117],"disease-specific":[120],"cohort":[121],"15":[124],"breast":[125],"cancer":[126],"(median":[128],"age,":[129],"55":[130],"years;":[131],"range,":[132],"28-66":[133],"years)":[134],"receiving":[135],"120":[136],"mg/kg/day":[137],"FEC100.":[142],"Partial":[143],"responses":[144,159],"seen":[146,161],"9":[148,163],"41":[150],"(22%)":[151],"during":[153],"part.":[157],"Objective":[158],"14":[165],"(64%)":[166],"evaluable":[167],"median":[175],"number":[176],"6":[178],"administered":[179],"cycles.":[180],"Predominant":[181],"toxicities":[182],"acid-associated":[185],"somnolence":[186],"epirubicin-induced":[188],"myelosuppression.":[189],"Valproic":[190,233],"associated":[195],"short-term,":[197],"reversible":[198],"depletion":[199],"WBC":[201],"neutrophils":[203],"within":[204],"48":[205],"hours.":[206],"Histone":[207],"samples":[211],"PBMCs":[214,242],"correlated":[215],"further":[222,259],"linked":[223],"but":[227],"not":[228],"expression.":[231],"CONCLUSION:":[232],"is":[235],"clinically":[237],"relevant":[238,263],"HDAC":[239],"may":[243],"serve":[244],"surrogate":[247],"for":[248],"should":[257],"be":[258],"considered":[260],"target.":[265]},"counts_by_year":[{"year":2026,"cited_by_count":3},{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":2},{"year":2023,"cited_by_count":2},{"year":2022,"cited_by_count":4},{"year":2021,"cited_by_count":5},{"year":2020,"cited_by_count":9},{"year":2019,"cited_by_count":10},{"year":2018,"cited_by_count":10},{"year":2017,"cited_by_count":10},{"year":2016,"cited_by_count":11},{"year":2015,"cited_by_count":7},{"year":2014,"cited_by_count":10},{"year":2013,"cited_by_count":12},{"year":2012,"cited_by_count":11}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}